Socialiya - Entertainment. Knowledge. Community.
Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial

Revolution Medicines' pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic...

BUSINESS NEWS April 13, 2026

Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial

Revolution Medicines' pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than...

18 views 0 likes 0 comments
Share:
Revolution Medicines' pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than...

Author: Fierce Biotech

Read Original Article

Related News

Advertisement
APNA POS
Advertisement
socialiya
Advertisement

Top Categories

Advertisement
APNA POS
Advertisement
APNA POS
Advertisement
APNA POS
Advertisement
APNA POS